Artiva Biotherapeutics Inc.

ARTV | NASDAQ

Price Alert Chart Builder DCF Calculator

$7.83

-$0.78 (-9.06%)

At close: Sep 21, 2026, 4:00 PM ET

$7.80

-$0.03 (-0.38%)

Pre-market: Sep 22, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-9.06%

(1D)

Rating

Updated: Aug 25, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $382.81M

1D Range

7.78 8.42

52W Range

2.52 14.53

Valuation (TTM)

PE -2.37

PB 1.10

EV/EBITDA -0.49

Valuation (NTM)

Forward PE N/A

Forward PEG -0.61

Price Target $37.50

Cash Flow

FCF Yield -25.6%

SBC Adj. FCF Yield -27.8%

SBC Impact -8.4%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | -10.7%

Dil EPS 3Y | 5Y -36.1% | -1.7%

FCF 3Y | 5Y -31.7% | -23.7%

Returns

ROA -24.6%

ROE -53.9%

ROIC -26.9%

Financial Health

Net Cash

$349.39M

Current Ratio 24.16

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and...

Sector Healthcare

Industry Biotechnology

Employees 115

IPO Date Jul 18, 2024

Website www.artivabio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$37.50

Upside

+378.93%

Buy (4)

Hold (0)

Sell (0)

Analyst Details ➞